Subcutaneous Injections

Eisai Secures FDA Approval for Leqembi Autoinjector for Maintenance Dosing in Alzheimer’s Patients

2 weeks ago talkbio0Tagged Alzheimer 's disease, Approved, at-home, AutoInjector, Biogen, dosing, Eisai, Lecanemab, Leqembi, Maintenance, Subcutaneous Injections, United States Food and Drug Administration

Eisai; Leqembi; lecanemab; FDA approval; autoinjector; subcutaneous injection; maintenance dosing; Alzheimer’s disease; at-home treatment; Biogen

FDA Approves CSL’s Andembry, Directly Competing With Takeda’s Takhzyro in HAE

3 months ago talkbio0Tagged Andembry, Angioedemas, Hereditary, Approved, dosing, factor XIIa, garadacimab-gxii, Inhibitor, SMPX gene, Subcutaneous Injections, Takeda, Takhzyro, United States Food and Drug Administration

Andembry; garadacimab-gxii; FDA approval; hereditary angioedema; HAE; CSL; Takhzyro; Takeda; factor XIIa inhibitor; once-monthly dosing; subcutaneous injection

FDA Approves Ocrevus Zunovo: A Breakthrough Subcutaneous Injection for Multiple Sclerosis

1 year ago talkbio0Tagged Approved, drug delivery technology, ENHANZE, Halozyme, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Ocrevus Zunovo, PPMS, Progressive, Relapsing Multiple Sclerosis, RMS, Subcutaneous Injections, United States Food and Drug Administration

Ocrevus Zunovo, FDA Approval, Subcutaneous Injection, Multiple Sclerosis, Relapsing Multiple Sclerosis (RMS), Primary Progressive Multiple Sclerosis (PPMS), Halozyme Therapeutics, ENHANZE drug delivery technology.